You Searched For: uPA+Inhibitor+II

29,957 results were found

Refine Results Sort by

Sort Results

List View Easy View

Compare(0) Clear

Rate These Search Results

uPA Inhibitor II, solid

Supplier: Thermo Scientific Chemicals

Description: A cell-permeable oxazolidinone-carboxamidine compound that acts as a potent, selective, and active-site targeting inhibitor of urokinase-type plasminogen activator

SDS Certificates

(-)-Epigallocatechin gallate ≥98% (by HPLC)

Supplier: Adipogen

Description: Potent anticancer compound. Anti-angiogenic. VEGF, VE-cadherin phosphorylation, matrix metalloproteinase and urokinase-plasminogen activator (uPA) inhibitor. Anti-inflammatory. NF-kappaB inhibitor. Modulates chronic inflammatory diseases, such as type 2 diabetes, rheumatoid arthritis, inflammatory bowel disease. COX-2 and inducible nitric oxide synthase (iNOS; NOS II) inhibitor. Potent antioxidant. Protects cells from lipid peroxidation and DNA damage induced by reactive free radicals. Regulates cancer cell growth, proliferation, transformation, survival, angiogenesis, apoptosis, invasion and metastasis. Chemopreventive. Apoptosis inducer. Promotes cell cycle arrest. Modulates signal transduction pathways including JAK/STAT, MAPK, PI3K/AKT, Wnt and Notch. EGFR and HER-2 receptor signaling inhibitor. MAPKs and activator protein-1 inhibitor. mTOR suppressor. IGF-I signaling inhibitor. Proteasome inhibitor. Telomerase and DNA methyltransferase inhibitor. Selective and noncompetitive HAT inhibitor. Topoisomerase I and II inhibitor. Hedgehog signaling (Hh) modulator. PTCH and Gli1 inhibitor. Wnt signaling inhibitor. Neuroprotective. Activates HO-1 by the ARE/Nrf2 pathway, protecting neurons against oxidative damage. STAT-1 inhibitor. Shows preventive cardiovascular and metabolic (obesity, insulin resistance, hypertension and hypercholesterolemia) effects. Inhibits extracellular signal-related kinases (ERK), activates AMP-activated protein kinase (AMPK), modulates adipocyte marker proteins and down-regulates lipogenic enzymes as well as other potential targets. Fatty acid synthase (FAS) inhibitor. Autophagy stimulator.

Calbiochem® 1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone, DiHCl

Catalog Number: (80056-266)

Supplier: MilliporeSigma

Description: Effective irreversible inhibitor of uPA, Factor Xa, and urokinase

SDS Certificates

Retrieving Each

Anti-SERPINE1 Rabbit Polyclonal Antibody

Catalog Number: (76012-336)

Supplier: Prosci

Description: This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Retrieving Each

Human Recombinant Serpin E2 (from HEK293 Cells)

Catalog Number: (10798-350)

Supplier: Prosci

Description: SERPINE2 is also known as Glia-derived nexin (GDN), Peptidase inhibitor 7 (PI7), Protease nexin 1(PN1). SERPINE2 is a secreted glycoprotein which belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). PAI-1 / GDN is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis. Defects in Serpin E1 / PN1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma.

Retrieving Each

Human Recombinant PAI-2 (from E. coli)

Supplier: Peprotech

Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa, nonglycosylated, intracellular protein, which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular, dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy, and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant Human PAI-2 is a 46.5 kDa, nonglycosylated protein of 415 residues.

Gabexate mesylate ≥98% (by HPLC)

Supplier: Enzo Life Sciences

Description: A competitive, reversible inhibitor of serine proteases tryptase (Ki=3.4nM), thrombin (Ki=500nM), uPA (Ki=1.3µM), plasmin (Ki=1.5µM), trypsin (Ki=2µM), factor Xa (Ki=2µM). At higher concentrations it inhibits kallikrein-1 (Ki=2.6mM), C1 esterase (IC50=520µM), as well as phospholipase A2 (IC50=500µM), rat iNOS (Ki=5mM) and cNOS (Ki=150µM), and swine kidney copper amine oxidase (Ki=27µM), but not chymotrypsin. Has been used in tissue culture and in vivo. In clinical use for pancreatitis.

Amiloride hydrochloride ≥98%

Supplier: ALADDIN SCIENTIFIC

Description: Amiloride ? HCl is a selective T-type calcium channel protein inhibitor that has been shown to inhibit the Polycystin-L channel (Polycystic kidney disease 2-like 1 protein: PKD2L1), a member of the transient receptor potential (TRP) superfamily of cation channels, including the NHE (sodium/hydgrogen exchanger). Amiloride is also an epithelial sodium channel protein inhibitor, which inhibits sodium reabsorption without affecting potassium concentrations. Amiloride serves as a non-selective acid-sensing ion channel (ASIC) blocker and a selective inhibitor of uPA (urokinase plasminogen activator). Research shows that amiloride reduces electrical potential across tubular epithelium, inhibits angiogenesis and inhibits capillary morphogenesis completely and reversibly at approximately 130 μM. Amiloride ? HCl is an inhibitor of Sodium/Potassium-ATPase Protein.A calcium channel andsodium channel protein inhibitor

New Product

Human Recombinant PAI2 (from E. coli)

Catalog Number: (10072-644)

Supplier: Prosci

Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa nonglycosylated intracellular protein which can be induced to be secreted as 60 kDa glycoprotein. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/mL), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant human PAI-2 is a 415-residue nonglycosylated protein.

Retrieving Each

Human Recombinant Serpin A5 (from Cells)

Catalog Number: (75789-646)

Supplier: Prosci

Description: Serpin A5 is a member of the human Serpin superfamily consists of at least 35 members. It is synthesized in the liver and has been detected in saliva, cerebral spinal fluid, amniotic fluid, tears and semen. As a potent inhibitor of the protein C anticoagulant pathway at the levels of both zymogen activation and enzyme inhibition, Serpin A5 additionally inhibits a variety of serine protease including thrombin, factor Xa, several kallekreins and acrosin. It plays a critical role in the processes of blood of blood coagulation and fertilization. Serpin A5 also inhibits urinary plasminogen activator (uPA), a mediator of tumor cell invasion, and regulates tumor growth and metastasis by inhibiting angiogenesis. Furthermore, recent studies have identified PCI as a potent and direct inhibitor of activated HGFA (hepatocyte growth factor activator), suggesting a novel function in the regulation of tissue repair and regeneration. Similar to Serpins C1 and D1, the thrombin inhibitory activity of serpinA5 is enhanced by heparin.

Retrieving Each

Curcumin, high purity

Supplier: Adipogen

Description: Anti-cancer compound. Interferes with multiple cell signaling pathways, including cell cycle (cyclin D1 and cyclin E), apoptosis (activation of caspases and down-regulation of anti-apoptotic gene products), proliferation (HER-2, EGFR and AP-1), survival (PI3K/AKT pathway), invasion (MMP-9 and adhesion molecules), angiogenesis (VEGF), metastasis (CXCR-4) and inflammation (NF-kappaB, TNF, IL-6, IL-1, COX-2 and 5-LOX). Anti-angiogenic. Anti-metastatic. Anti-invasive. Chemopreventive. Sonic hedgehog (Shh) signaling pathway modulator. Downregulates Shh and Gli1. Antioxidant. Anti-inflammatory. Potent inhibitor of NF-kappaB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS; NOSII). Downregulates the expression of various proinflammatory cytokines including TNF, IL-1, IL-2, IL-6, IL-8, IL-12 and chemokines. Potent immunomodulator. Modulates several key transcription factors. Down-regulate transcription factors NF-kappaB, AP-1 and Egr-1. Down-regulates the expression of COX-2, LOX, NOS, MMP-9, uPA, TNF, chemokines, cell surface adhesion molecules and cyclin D1. Down-regulate growth factor receptors (such as EGFR and HER2) and inhibits the activity of c-Jun N-terminal kinase, protein tyrosine kinases and protein serine/threonine kinases. Neuroprotective. Anti-amyloid activity. Cardioprotective. p300/CBP-HAT inhibitor. Regulates lipid metabolism and downregulates obesity. Activates peroxisome proliferator-activated receptor-gamma (PPARgamma) and Nrf2 cell-signaling pathways. Antiviral, antibacterial, antifungal. Epigenetic agent. Interacts with histone deacetylases (HDACs), histone acetyltransferases (HATs), DNA methyltransferase I and microRNAs. Inducer of autophagy in lung adenocarcinoma cells.